How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Oncology Radiopharmaceutical Market
- By Product Type: Therapeutic Radiopharmaceuticals, Diagnostic Radiopharmaceuticals, Theranostic Radiopharmaceuticals
- By Radioisotope Type: Lutetium-177 (Lu-177), Radium-223 (Ra-223), Iodine-131 (I-131), Yttrium-90 (Y-90), Actinium-225 (Ac-225)
- By Cancer Indication: Prostate Cancer, Neuroendocrine Tumors, Breast Cancer, Lung Cancer, Bone Metastases
- By End User: Hospitals, Specialty Clinics, Diagnostic Centers, Research Institutes
- By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Direct Sales, Third-Party Distributors
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Therapeutic Radiopharmaceuticals leads By Product Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 298 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.179 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.187 →
Full report · locked preview
Everything inside the Oncology Radiopharmaceutical Market report
A complete, evidence-based study - 12 chapters and 125 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Product Type 3
Radioisotope Type 5
Cancer Indication 5
End User 4
Distribution Channel 4
Companies profiled
Novartis AG
Bayer AG
Lantheus Holdings Inc.
Telix Pharmaceuticals Limited
Advanced Accelerator Applications (AAA) - a Novartis company
Blue Earth Diagnostics Ltd.
ITM Isotopen Technologien München AG
Curium Pharma
Point Biopharma Global Inc.
Endocyte
Inc. (a Novartis company)
Actinium Pharmaceuticals Inc.
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Novartis AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Bayer AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Lantheus Holdings Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Telix Pharmaceuticals Limited
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Advanced Accelerator Applications (AAA) - a Novartis company
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Blue Earth Diagnostics Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →ITM Isotopen Technologien München AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Curium Pharma
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Point Biopharma Global Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Endocyte
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Inc. (a Novartis company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Actinium Pharmaceuticals Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Fusion Pharmaceuticals Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →RadioMedix Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Jubilant Radiopharma
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Nordion (a Sotera Health company)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$5,333M by 2033 · 11.1% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Therapeutic Radiopharmaceuticals46.0
- Diagnostic Radiopharmaceuticals25.2
- Theranostic Radiopharmaceuticals28.8
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$757.3M → $1,773M · 11.2%
Europe$527.8M → $1,118M · 9.8%
Asia Pacific$481.9M → $1,255M · 12.7%
Latin America$298.3M → $757.6M · 12.4%
Middle East and Africa$229.5M → $543.4M · 11.4%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →11.072026
11.092027
11.092028
11.112029
11.112030
11.142031
11.152032
11.142033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Novartis AG21.8
- Bayer AG22.3
- Lantheus Holdings Inc.9.0
- Telix Pharmaceuticals Limited4.7
- Advanced Accelerator Applications (AAA) - a Novartis company6.9
- Blue Earth Diagnostics Ltd.7.3
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Product Type11.0%
Radioisotope Type31.8%
Cancer Indication17.2%
End User22.7%
Distribution Channel17.4%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.6
- Europe20.5
- Asia Pacific23.0
- Latin America13.9
- Middle East and Africa10.0
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Novartis AG | 85 | 92 | 96 | 75 | 86 | 92 | 88 |
| Bayer AG | 74 | 84 | 90 | 70 | 88 | 93 | 83 |
| Lantheus Holdings Inc. | 75 | 84 | 65 | 66 | 76 | 66 | 72 |
| Telix Pharmaceuticals Limited | 66 | 79 | 58 | 59 | 66 | 61 | 65 |
| Advanced Accelerator Applications (AAA) - a Novartis company | 57 | 55 | 61 | 66 | 67 | 76 | 64 |
| Blue Earth Diagnostics Ltd. | 59 | 65 | 48 | 60 | 65 | 71 | 61 |
| ITM Isotopen Technologien München AG | 52 | 58 | 51 | 56 | 60 | 46 | 54 |
| Curium Pharma | 56 | 60 | 39 | 50 | 60 | 35 | 50 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Novartis AG
- Bayer AG
- Lantheus Holdings Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Novartis AG | ✓ | ✓ | ✓ | ✓ | ◐ | ✓ |
| Bayer AG | ◐ | ✓ | ✓ | ◐ | ✓ | ✓ |
| Lantheus Holdings Inc. | ◐ | ✓ | − | ◐ | ✓ | − |
| Telix Pharmaceuticals Limited | ✓ | ✓ | − | − | ◐ | ◐ |
| Advanced Accelerator Applications (AAA) - a Novartis company | − | ◐ | ◐ | ✓ | ◐ | ✓ |
| Blue Earth Diagnostics Ltd. | ◐ | ✓ | − | − | ◐ | ◐ |
| ITM Isotopen Technologien München AG | ◐ | ◐ | − | ◐ | ◐ | − |
| Curium Pharma | − | − | − | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Novartis AG88
2Bayer AG83
3Lantheus Holdings Inc.72
4Telix Pharmaceuticals Limited65
5Advanced Accelerator Applications (AAA) - a Novartis company64
6Blue Earth Diagnostics Ltd.61
7ITM Isotopen Technologien München AG54
8Curium Pharma50
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Novartis AGBayer AG
Challenger1
Strong scale, closing on the leaders.
Lantheus Holdings Inc.
Contender3
Focused players with pockets of strength.
Telix Pharmaceuticals LimitedAdvanced Accelerator Applications (AAA) - a Novartis companyBlue Earth Diagnostics Ltd.
Niche2
Specialists in a single segment or region.
ITM Isotopen Technologien München AGCurium Pharma
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Product Type in North America, then scale across Oncology Radiopharmaceutical Market — a $39M beachhead inside a $637M market.
Beachhead (SOM)$39Mobtainable near-term
Serviceable (SAM)$253Mreachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Therapeutic Radiopharmaceuticals
Best fit — highest urgency & budget in Product Type.
Economic buyer75 fit
Diagnostic Radiopharmaceuticals
Strong fit — clear ROI and a fast path to value.
End user70 fit
Theranostic Radiopharmaceuticals
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Product Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Radioisotope Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Cancer Indication
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales47%
Partner / channel29%
Digital / self-serve17%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Product Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Oncology Radiopharmaceutical Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified20%
Evaluation11%
Closed-won6%
$18.3KCAC
$65KLTV
3.5:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Oncology Radiopharmaceutical Market is a durable-growth opportunity — $1.92B by 2033, compounding at 9.4%.
TAM · 2025$936Mtoday
TAM · 2033$1.92Bforecast
CAGR9.4%2027–2033
Cumulative$12.4Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$1.92BTotal addressable market
SAM$713MServiceable available market
SOM$114MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →9.4% CAGR
Demand compounds through 2033, outpacing GDP across Product Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Product Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$1.92BLarge & growingTAM by 2033 at 9.4% CAGR
$713MServiceable nowreachable with today’s model
$114MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$1.50BBear6.1% CAGR
$1.92BBase9.4% CAGR
$2.46BBull12.4% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Radioisotope Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Oncology Radiopharmaceutical Market — a $3.15B market by 2033. Plan: grow share from 9.1% to 17.9%.
Market size · 2033$3.15Btotal addressable
Market CAGR9.4%2027–2033
Target share17.9%from 9.1% today
Revenue ambition$565Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.1% | 17.9% | Behind |
| Revenue | $303M | $565M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 32.6% | 44.3% | At risk |
| Customer retention | 89.9% | 92.7% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Product Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Radioisotope Type capability
A defensible second engine — invest in Radioisotope Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Product Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Radioisotope Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $57M capacity & capability investment
- Greenlight bolt-on M&A in Radioisotope Type
- Authorise North America expansion plan
- Fund R&D program for Product Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeAhead
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Oncology Radiopharmaceutical Market conversation — a $4.24B market you can size, segment and defend in minutes.
Market size · 2033$4.24Btotal opportunity
Growth3.4%CAGR to 2033
Addressable buyers1,071+accounts in scope
Typical ROI6.2×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Product Type
Goal Grow share in Product Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.2×return on cost, year one
< 3 mopayback period
$58K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Novartis AGBayer AGLantheus Holdings Inc.Telix Pharmaceuticals LimitedAdvanced Accelerator Applications (AAA) - a Novartis companyBlue Earth Diagnostics Ltd.ITM Isotopen Technologien München AGCurium Pharma+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Oncology Radiopharmaceutical Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Oncology Radiopharmaceutical Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Oncology Precision Medicine Market
Market size, share, segmentation and regional forecast.
$351M market · 2025 base year
View reportOncology Nutrition Deals Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportOncology Medication Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportOncology Informatics Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportOncology Immunotherapy Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportOncology Immuno Drug Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportOncology Electronic Medical Records (EMR) Software Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportOncology Drug Discovery Services Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportOncology Companion Diagnostic Market
Market size, share, segmentation and regional forecast.
$1.0B market · 2025 base year
View reportOncology Clinical Imaging Solutions Market
Market size, share, segmentation and regional forecast.
$563M market · 2025 base year
View reportOncology Blood Testing Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportOncology Based Preclinical CRO Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.